Recent advances in multiple myeloma treatment, including protease inhibitors, immunomodulating agents, and monoclonal antibodies, have given patients more options and enhanced quality of life than ever before. Despite these advances, multiple myeloma remains an incurable disease and treatment for relapsed/refractory (R/R) patients continues to be a pressing need. The emergence of chimeric antigen receptor T-cell (CAR-T) therapy promises a new wave of innovation and treatment progress on the horizon.
Fill in the form below to access an overview of our Multiple Myeloma syndicated study including:
- Types of data collected
- Dates of research waves